Top

Published in:

Open Access 01-04-2015 | Review Article

Managing patients with advisory defibrillator leads: what can we learn from published data?

Authors: F. A. Bracke, B. M. van Gelder

Published in: Netherlands Heart Journal | Issue 4/2015

Abstract

Defibrillator lead advisories stir a lot of emotions, both with patients and physicians, and this may influence lead management. We reviewed the literature for a more evidence-based approach to this issue.

From the complications of two of the current advisory leads, the Medtronic Sprint Fidelis and St. Jude Riata leads, and the consequences of possible interventions, we can conclude that a restrained approach to premature replacement is appropriate. It may be opportune to replace the leads during a scheduled generator replacement in case of a higher electrical failure rate, in order to prevent future premature interventions.

We found no support to extract non-functional advisory leads. In contrast, extraction is often more demanding than anticipated, and the risk substantially exceeds that of simply abandoning the leads.

Kay GN, Brinker JA, Kawanishi DT, et al. Risks of spontaneous injury and extraction of an active fixation pacemaker lead: report of the Accufix Multicenter Clinical Study and Worldwide Registry. Circulation. 1999;100:2344–52.CrossRefPubMed

Maisel WH, Hauser RG, Hammill SC, et al. Recommendations from the Heart Rhythm Society task force on lead performance policies and guidelines: developed in collaboration with the American College of Cardiology and the American Heart Association. Heart Rhythm. 2009;6:869–85.CrossRefPubMed

Abdelhadi RH, Saba SF, Ellis CR, et al. Independent multicenter study of Riata and Riata ST implantable cardioverter-defibrillator leads. Heart Rhythm. 2013;10:361–5.CrossRefPubMed

Hayes D, Freedman R, Curtis AB, et al. Prevalence of externalized conductors in Riata and Riata ST silicone leads: Results from the prospective, multicenter Riata Lead Evaluation Study. Heart Rhythm. 2013;10:1778–82.CrossRefPubMed

Parkash R, Exner D, Champagne J, et al. Failure rate of the Riata lead under advisory: a report from the CHRS Device Committee. Heart Rhythm. 2013;10:692–5.CrossRefPubMed

Barrett CD, Danik SB. The Riata lead recall—more data, but do we now know what we need to know? Heart Rhythm. 2013;10:1783–4.CrossRefPubMed

Kleemann T, Becker T, Doenges K, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007;115:2474–80.CrossRefPubMed

Demirel F, Adiyaman A, Delnoy PPHM, Smit JJJ, Ramdat Misier AR, Elvan A. Mechanical and electrical dysfunction of Riata implantable cardioverter-defibrillator leads. Europace. 2014;16:1787–94.CrossRefPubMed

Theuns DAMJ, Elvan A, Voogt W de, Cock CC de, Erven L van, Meine M. Prevalence and presentation of externalized conductors and electrical abnormalities in Riata defibrillator leads after fluoroscopic screening: report from The Netherlands Heart Rhythm Association Device Advisory Committee. Circ Arrhythm Electrophysiol. 2012;5:1059–63.CrossRefPubMed

10.

http://www.medtronic.com/product-advisories/physician/sprint-fidelis/6949-LEAD–PERFORMANCE. Accessed on 20 February 2015.

11.

Birnie DH, Parkash R, Exner DV, et al. Clinical predictors of Fidelis lead failure: report from the Canadian Heart Rhythm Society Device Committee. Circulation. 2012;125:1217–25.CrossRefPubMed

12.

Hauser RG, Abdelhadi R, McGriff D, Retel LK. Deaths caused by the failure of Riata and Riata ST implantable cardioverter-defibrillator leads. Heart Rhythm. 2012;9:1227–35.CrossRefPubMed

13.

Morrison TB, Friedman PA, Kallinen LM, et al. Impact of implanted recalled sprint Fidelis lead on patient mortality. J Am Coll Cardiol. 2011;58:278–83.CrossRefPubMed

14.

van Welsenes GH, van Rees JB, Borleffs CJW, et al. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace. 2011;13:389–94.CrossRefPubMed

15.

Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.CrossRefPubMed

16.

Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.CrossRefPubMed

17.

Bashir J, Cowan S, Raymakers A, et al. A cost-effectiveness analysis of a proactive management strategy for the Sprint Fidelis recall: a probabilistic decision analysis model. Heart Rhythm. 2013;10:1761–7.CrossRefPubMed

18.

Wilkoff BL, Williamson BD, Stern RS, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008;52:541–50.CrossRefPubMed

19.

Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367:2275–83.CrossRefPubMed

20.

Wijers SC, Kolk BYM van der, Tuinenburg AE, Doevendans PAF, Vos MA, Meine M. Implementation of guidelines for implantable cardioverter-defibrillator therapy in clinical practice: which patients do benefit? Neth Heart J 2013;21:274–83.CrossRefPubMedCentralPubMed

21.

Krahn AD, Champagne J, Healey JS, et al. Outcome of the Fidelis implantable cardioverter-defibrillator lead advisory: a report from the Canadian Heart Rhythm Society Device Advisory Committee. Heart Rhythm. 2008;5:639–42.CrossRefPubMed

22.

Sung RK, Massie BM, Varosy PD, et al. Long-term electrical survival analysis of Riata and Riata ST silicone leads: National Veterans Affairs experience. Heart Rhythm. 2012;9:1954–61.CrossRefPubMed

23.

Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009–17.CrossRefPubMedCentralPubMed

24.

Pedersen SS, Hoogwegt MT, Jordaens L, Theuns DAMJ. Procedure- and device-related complications and psychological morbidity in implantable cardioverter defibrillator patients. Int J Cardiol. 2013;168:606–7.CrossRefPubMed

25.

Keren A, Sears SF, Nery P, et al. Psychological adjustment in ICD patients living with advisory fidelis leads. J Cardiovasc Electrophysiol. 2011;22:57–63.CrossRefPubMed

26.

Magyar-Russell G, Thombs BD, Cai JX, et al. The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: a systematic review. J Psychosom Res. 2011;71:223–31.CrossRefPubMed

27.

Kallinen LM, Hauser RG, Tang C, et al. Lead integrity alert algorithm decreases inappropriate shocks in patients who have Sprint Fidelis pace-sense conductor fractures. Heart Rhythm. 2010;7:1048–55.CrossRefPubMed

28.

Swerdlow CD, Gunderson BD, Ousdigian KT, Abeyratne A, Sachanandani H, Ellenbogen KA. Downloadable software algorithm reduces inappropriate shocks caused by implantable cardioverter-defibrillator lead fractures: a prospective study. Circulation. 2010;122:1449–55.CrossRefPubMed

29.

Hauser RG, Hayes DL. Increasing hazard of Sprint Fidelis implantable cardioverter-defibrillator lead failure. Heart Rhythm. 2009;6:605–10.CrossRefPubMed

30.

Johansen JB, Jørgensen OD, Møller M, Arnsbo P, Mortensen PT, Nielsen JC. Infection after pacemaker implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299 consecutive patients. Eur Heart J. 2011;32:991–8.CrossRefPubMedCentralPubMed

31.

Gould PA, Krahn AD, Canadian Heart Rhythm Society Working Group on Device Advisories. Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA. 2006;295:1907–11.CrossRefPubMed

32.

Costea A, Rardon DP, Padanilam BJ, Fogel RI, Prystowsky EN. Complications associated with generator replacement in response to device advisories. J Cardiovasc Electrophysiol. 2008;19:266–9.CrossRefPubMed

33.

Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation. 2010;122:1553–61.CrossRefPubMed

34.

Eckstein J, Koller MT, Zabel M, et al. Necessity for surgical revision of defibrillator leads implanted long-term: causes and management. Circulation. 2008;117:2727–33.CrossRefPubMed

35.

Olde Nordkamp LRA, Knops RE, Bardy GH, et al. Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. Am Heart J. 2012;163:753–60.e2.CrossRefPubMed

36.

Wilkoff BL, Love CJ, Byrd CL, et al. Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management. Heart Rhythm. 2009;6:1085–104.CrossRefPubMed

37.

Maytin M, Wilkoff BL, Brunner M, et al. Multicenter experience with extraction of the Riata/Riata ST ICD lead. Heart Rhythm. 2014;11:1613–8.CrossRefPubMed

38.

Bohm A, Pinter A, Duray G, et al. Complications due to abandoned noninfected pacemaker leads. Pacing Clin Electrophysiol. 2001;24:1721–4.CrossRefPubMed

39.

Suga C, Hayes D, Hyberger L, Lloyd M. Is there an adverse outcome from abandoned pacing leads? J Interv Card Electrophysiol. 2000;4:493–9.CrossRefPubMed

40.

Glikson M, Suleiman M, Luria DM, et al. Do abandoned leads pose risk to implantable cardioverter-defibrillator patients? Heart Rhythm. 2009;6:65–8.CrossRefPubMed

41.

Bode F, Himmel F, Reppel M, Mortensen K, Schunkert H, Wiegand UKH. Should all dysfunctional high-voltage leads be extracted? Results of a single-centre long-term registry. Europace. 2012;14:1764–70.CrossRefPubMed

42.

Amelot M, Foucault A, Scanu P, et al. Comparison of outcomes in patients with abandoned versus extracted implantable cardioverter defibrillator leads. Arch Cardiovasc Dis. 2011;104:572–7.CrossRefPubMed

43.

Bracke F, Meijer A, Gelder LM van. Symptomatic occlusion of the access vein after pacemaker or ICD lead extraction. Heart. 2003;89:1348–9.CrossRefPubMedCentralPubMed

44.

Cock C de, Vinkers M, Campe L Van, Verhorst P, Visser C. Long-term outcome of patients with multiple (> or = 3) noninfected transvenous leads: a clinical and echocardiographic study. Pacing Clin Electrophysiol. 2000;23:423–6.CrossRefPubMed

45.

Ricciardi D, La Meir M, Asmundis C de, Brugada P. A case of in vivo thrombogenicity of an externalized Riata ST lead. Europace. 2013;15:428.CrossRefPubMed

46.

Goyal SK, Ellis CR, Rottman JN, Whalen SP. Lead thrombi associated with externalized cables on Riata ICD leads: a case series. J Cardiovasc Electrophysiol. 2013;24:1047–50.CrossRefPubMed

47.

Pfeiffer D, Jung W, Fehske W, et al. Complications of pacemaker-defibrillator devices: diagnosis and management. Am Heart J. 1994;127:1073–80.CrossRefPubMed

48.

Venkataraman G, Hayes DL, Strickberger SA. Does the risk-benefit analysis favor the extraction of failed, sterile pacemaker and defibrillator leads? J Cardiovasc Electrophysiol. 2009;20:1413–5.CrossRefPubMed

49.

Mehrotra AK, Knight BP, Smelley MP, et al. Medtronic Sprint Fidelis lead recall: determining the initial 5-year management cost to Medicare. Heart Rhythm. 2011;8:1192–7.CrossRefPubMed

50.

Maytin M, Love CJ, Fischer A, et al. Multicenter experience with extraction of the Sprint Fidelis implantable cardioverter-defibrillator lead. J Am Coll Cardiol. 2010;56:646–50.CrossRefPubMed

51.

Parkash R, Crystal E, Bashir J, et al. Complications associated with revision of Sprint Fidelis leads: report from the Canadian Heart Rhythm Society Device Advisory Committee. Circulation. 2010;121:2384–7.CrossRefPubMed

52.

Patel D, Adelstein E, Nemec J, et al. Extraction of defibrillator leads recalled for cable externalization and failure. J Interv Card Electrophysiol. 2012;34:105–13.CrossRef

53.

Brunner MP, Cronin EM, Jacob J, et al. Transvenous extraction of implantable cardioverter-defibrillator leads under advisory–a comparison of Riata, Sprint Fidelis, and non-recalled implantable cardioverter-defibrillator leads. Heart Rhythm. 2013;10:1444–50.CrossRefPubMed

54.

Brunner MP, Cronin EM, Duarte VE, et al. Clinical predictors of adverse patient outcomes in an experience of more than 5000 chronic endovascular pacemaker and defibrillator lead extractions. Heart Rhythm. 2014;11:799–805.CrossRefPubMed

Title: Managing patients with advisory defibrillator leads: what can we learn from published data?
Authors: F. A. Bracke
B. M. van Gelder
Publication date: 01-04-2015
Publisher: Bohn Stafleu van Loghum
Published in: Netherlands Heart Journal / Issue 4/2015
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI: https://doi.org/10.1007/s12471-015-0669-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Managing patients with advisory defibrillator leads: what can we learn from published data?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

Guidance on guideline adherence

What is the Origin of the Ectopic Beat?

CVON: a laudable strategy waiting for societal impact

Secundum atrial septal defect in adults: a practical review and recent developments

Multivessel revascularisation versus infarct-related artery only revascularisation during the index primary PCI in STEMI patients with multivessel disease: a meta-analysis

Right ventricular function in dilated cardiomyopathy and ischemic heart disease: assessment with non-invasive imaging

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page